Comorbidities are associated with fibrosis ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Comorbidities are associated with fibrosis in nafld subjects: a nationwide study (nash-co study)
Auteur(s) :
Nabi, Oumarou [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Boursier, Jerome [Auteur]
Université d'Angers [UA]
Centre Hospitalier Universitaire d'Angers [CHU Angers]
Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques [HIFIH]
Lacombe, Karine [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Sorbonne Université [SU]
CHU Saint-Antoine [AP-HP]
Mathurin, Philippe [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
De Ledinghen, Victor [Auteur]
Bordeaux Research In Translational Oncology [Bordeaux] [BaRITOn]
Service d'Hépato-Gastro-Entérologie
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Goldberg, Marcel [Auteur]
Cohortes épidémiologiques en population [CONSTANCES]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Zins, Marie [Auteur]
Cohortes épidémiologiques en population [CONSTANCES]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Serfaty, Lawrence [Auteur]
Centre de Recherche Saint-Antoine [CRSA]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Boursier, Jerome [Auteur]
Université d'Angers [UA]
Centre Hospitalier Universitaire d'Angers [CHU Angers]
Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques [HIFIH]
Lacombe, Karine [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Sorbonne Université [SU]
CHU Saint-Antoine [AP-HP]
Mathurin, Philippe [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
De Ledinghen, Victor [Auteur]
Bordeaux Research In Translational Oncology [Bordeaux] [BaRITOn]
Service d'Hépato-Gastro-Entérologie
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Goldberg, Marcel [Auteur]
Cohortes épidémiologiques en population [CONSTANCES]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Zins, Marie [Auteur]
Cohortes épidémiologiques en population [CONSTANCES]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Serfaty, Lawrence [Auteur]
Centre de Recherche Saint-Antoine [CRSA]
Titre de la revue :
Digestive Diseases and Sciences
Nom court de la revue :
Dig Dis Sci
Date de publication :
2021-05-24
ISSN :
1573-2568
Mot(s)-clé(s) :
Chronic kidney disease
Colorectal cancer
Forns Index
Cancer
Cardiovascular disease
Fatty Liver Index
Colorectal cancer
Forns Index
Cancer
Cardiovascular disease
Fatty Liver Index
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
BACKGROUND: The relationship between the severity of NAFLD and extra-hepatic events such as cardiovascular disease (CVD), extra-hepatic cancer (EHC) or chronic kidney diseases (CKD) has not been clearly investigated in the ...
Lire la suite >BACKGROUND: The relationship between the severity of NAFLD and extra-hepatic events such as cardiovascular disease (CVD), extra-hepatic cancer (EHC) or chronic kidney diseases (CKD) has not been clearly investigated in the general population. OBJECTIVE: The aim of this study was to assess whether the severity of fibrosis in NAFLD subjects was associated with extra-hepatic diseases based on noninvasive markers in a large population-based cohort. METHODS: The study population included a cohort of 118,664 participants from the nationwide CONSTANCES cohort. After excluding individuals with excessive alcohol consumption and other causes of liver disease, 102,344 were included. The noninvasive diagnosis of NAFLD and fibrosis was performed using a combination of the Fatty Liver Index (FLI) and the Forns Index. The history of CVD or EHC was recorded by a physician, and CKD was defined by a glomerular filtration rate < 60 ml/mn. RESULTS: The prevalence of NAFLD (FLI > 60) was 18.2%, 10% with mild fibrosis (Forns Index < 4.2), 7.7% with intermediate fibrosis (Forns Index 4.2-6.9), and 0.4% with advanced fibrosis (Forns Index > 6.9). The prevalence of CVD, EHC, or CKD increased significantly with the severity of fibrosis (p < 0.0001). When adjusted for demographic, metabolic risk factors, and smoking, NAFLD with intermediate or advanced fibrosis remained associated with CVD (OR 1.36, p < 0.0001 and OR 3.07, p < 0.0001, respectively), EHC (OR 1.24, p = 0.001 and OR 1.64, p = 0.004, respectively), and CKD (OR 1.18, p = 0.03 and OR 2.09, p < 0.0001, respectively). CONCLUSIONS: In a large adult population-based cohort, there is a dose-dependent relationship between the severity of fibrosis and CVD, EHC, or CKD in NAFLD subjects.Lire moins >
Lire la suite >BACKGROUND: The relationship between the severity of NAFLD and extra-hepatic events such as cardiovascular disease (CVD), extra-hepatic cancer (EHC) or chronic kidney diseases (CKD) has not been clearly investigated in the general population. OBJECTIVE: The aim of this study was to assess whether the severity of fibrosis in NAFLD subjects was associated with extra-hepatic diseases based on noninvasive markers in a large population-based cohort. METHODS: The study population included a cohort of 118,664 participants from the nationwide CONSTANCES cohort. After excluding individuals with excessive alcohol consumption and other causes of liver disease, 102,344 were included. The noninvasive diagnosis of NAFLD and fibrosis was performed using a combination of the Fatty Liver Index (FLI) and the Forns Index. The history of CVD or EHC was recorded by a physician, and CKD was defined by a glomerular filtration rate < 60 ml/mn. RESULTS: The prevalence of NAFLD (FLI > 60) was 18.2%, 10% with mild fibrosis (Forns Index < 4.2), 7.7% with intermediate fibrosis (Forns Index 4.2-6.9), and 0.4% with advanced fibrosis (Forns Index > 6.9). The prevalence of CVD, EHC, or CKD increased significantly with the severity of fibrosis (p < 0.0001). When adjusted for demographic, metabolic risk factors, and smoking, NAFLD with intermediate or advanced fibrosis remained associated with CVD (OR 1.36, p < 0.0001 and OR 3.07, p < 0.0001, respectively), EHC (OR 1.24, p = 0.001 and OR 1.64, p = 0.004, respectively), and CKD (OR 1.18, p = 0.03 and OR 2.09, p < 0.0001, respectively). CONCLUSIONS: In a large adult population-based cohort, there is a dose-dependent relationship between the severity of fibrosis and CVD, EHC, or CKD in NAFLD subjects.Lire moins >
Langue :
Anglais
Comité de lecture :
Oui
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Date de dépôt :
2021-07-06T12:50:58Z
2024-03-05T11:13:57Z
2024-03-05T11:13:57Z
Fichiers
- s10620-021-07032-z.pdf
- Version éditeur
- Accès restreint
- Accéder au document